-
Innovation Ranking
Innovation Ranking – GB Group PLC
GB Group PLC (GB Group) is a provider of identity data intelligence services. The company offers fraud, risk and compliance solutions including business decisions automation, documents validation, application fraud detection, customer behaviour monitoring, and fraud sharing and access services. It also offers location and customer intelligence services including global address validation, global telephone number validation, bank account validation and email validation services. GB Group offers ID (identity document) verification, ID registration, ID engagement, ID trace and investigate solutions, ID employ...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – GB-2064 in Myelofibrosis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - GB-2064 in Myelofibrosis report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. GB-2064 in Myelofibrosis Drug Details: GB-2064 (PAT-1251) Is under development for the treatment...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Nomacopan in Thrombotic Microangiopathy
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Nomacopan in Thrombotic Microangiopathy report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Nomacopan in Thrombotic Microangiopathy Drug Details: Nomacopan is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – GB-2064 in Post-Polycythemia Vera Myelofibrosis (PPV-MF)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - GB-2064 in Post-Polycythemia Vera Myelofibrosis (PPV-MF) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. GB-2064 in Post-Polycythemia Vera Myelofibrosis (PPV-MF) Drug Details: GB-2064 (PAT-1251)...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – GB-2064 in Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - GB-2064 in Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. GB-2064 in Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF) Drug Details:...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Pelabresib in Myelofibrosis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Pelabresib in Myelofibrosis report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Pelabresib in Myelofibrosis Drug Details: Pelabresib (CPI-0610) is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – NKTR-255 in Solid Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - NKTR-255 in Solid Tumor report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. NKTR-255 in Solid Tumor Drug Details: NKTR-255 is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Pacmilimab in Gastric Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Pacmilimab in Gastric Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Pacmilimab in Gastric Cancer Drug Details: CX-072 is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Abemaciclib in Central Nervous System (CNS) Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Abemaciclib in Central Nervous System (CNS) Tumor report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Abemaciclib in Central Nervous System (CNS) Tumor Drug...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – HB-101 in Cytomegalovirus (HHV-5) Infections
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - HB-101 in Cytomegalovirus (HHV-5) Infections report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. HB-101 in Cytomegalovirus (HHV-5) Infections Drug Details: HB-101 (Vaxwave) is under...